ReviewFrontiers in cell and developmental biology2026
Endothelial system dysregulation underlies keloid development and therapeutic targeting.
Review in Frontiers in cell and developmental biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cutaneous keloids are pathological scars resulting from aberrant wound healing, characterized by infiltrative growth beyond the original wound margins and a failure to regress spontaneously. Although traditionally attributed to excessive extracellular matrix deposition and fibroblast proliferation, emerging evidence underscores the pivotal role of vascular dysregulation and endothelial dysfunction in keloid pathogenesis. This review systematically examines the endothelial cell system-comprising vascular endothelial cells (VECs) and lymphatic endothelial cells (LECs)-within the keloid microenvironment, focusing on how hypoxia, chronic inflammation, mechanical forces, sex hormones, the renin-angiotensin system, and neuropeptides converge to drive structural and functional endothelial abnormalities. Special emphasis is placed on endothelial-to-mesenchymal transition (EndMT) as a critical pathway linking vascular pathology to fibrotic progression. Additionally, we comprehensively summarize current and emerging therapeutic strategies targeting the endothelium, including anti-angiogenic agents, HIF-1α inhibition, EndMT blockade, mechanical offloading, hormonal modulation, renin-angiotensin system (RAS) inhibition, and laser therapy. By providing an integrated overview of the endothelial mechanisms underlying keloid formation and persistence, this review aims to illuminate novel targets for therapeutic intervention and to inform the development of more effective clinical management strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.